MAZ-Mediated ubiquitin-conjugating enzyme E2C upregulation promotes breast cancer progression via the MAPK signaling pathway
Translational Oncology · 2026-02 · 64 · 102646
DOI: 10.1016/j.tranon.2025.102646 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Oncology, 2026-02. Verfasst von Jinhui Bai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, China; Guangxi Key Laboratory of Molecula…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Guangxi Natural Science Foundation.
Abstract (Originalsprache)
BACKGROUND: Malignant proliferation and invasion of tumor cells are the primary causes of death among patients with breast cancer, yet the molecular mechanisms orchestrating cancer metastasis are not well elucidated. Ubiquitin-conjugating enzyme E2C (UBE2C) has been reported to be involved in the tumorigenesis and development of various malignant tumors; however, the biological roles and underlying mechanisms of UBE2C in breast cancer remain unclear. METHODS: UBE2C expression was analyzed in breast cancer tissue and cell lines using immunohistochemistry, quantitative reverse transcription PCR (RT-qPCR) and Western blot. The biological roles of UBE2C and its transcription factor MAZ were investigated in vitro using CCK-8, plate cloning, scratch, Transwell, cell cycle and apoptosis assays, while a nude mouse subcutaneous tumorigenic model was employed for the in vivo studies. Dual-luciferase reporter assay and chromatin immunoprecipitation (ChIP) assay were conducted to validate the binding relationship between MAZ and UBE2C. RESULTS: UBE2C expression is elevated in breast cancer, and higher levels of UBE2C are associated with poorer survival among patients with breast cancer. UBE2C promotes the progression of breast cancer both in vivo and in vitro. Additionally, UBE2C is a direct transcriptional target of MAZ, which also accelerates malignant development of breast cancer. Furthermore, UBE2C exerts its oncogenic effects dependent on the MAPK signaling pathway. CONCLUSION: Our findings highlight the critical role of the MAZ/UBE2C/MAPK signaling axis in the progression of breast cancer and identify potential novel therapeutic targets for its treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, China; Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair, the Affiliated Hospital of Guil…
- Department of Information, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, China.
- Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair, the Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, China; Guangxi Health Commission Key Laboratory of Basic Research in…
- Department of Anesthesiology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, China.
- Department of Nuclear Medicine, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, China.
Förderung
- National Natural Science Foundation of China
- Guangxi Natural Science Foundation
Zitieren
APA
Bai, J., Deng, M., Wu, X., Xiong, C., Wu, H., Wang, L., & Qin, J. (2026). MAZ-Mediated ubiquitin-conjugating enzyme E2C upregulation promotes breast cancer progression via the MAPK signaling pathway. Translational Oncology, 64, 102646. https://doi.org/10.1016/j.tranon.2025.102646
Vancouver
Bai J, Deng M, Wu X, Xiong C, Wu H, Wang L, et al. MAZ-Mediated ubiquitin-conjugating enzyme E2C upregulation promotes breast cancer progression via the MAPK signaling pathway. Translational Oncology. 2026;64:102646. doi:10.1016/j.tranon.2025.102646
BibTeX
@article{Bai2026,
author = {Bai, Jinhui and Deng, Mei and Wu, Xueting and Xiong, Chao and Wu, Huixian and Wang, Li and Qin, Jie},
title = {MAZ-Mediated ubiquitin-conjugating enzyme E2C upregulation promotes breast cancer progression via the MAPK signaling pathway},
journal = {Translational Oncology},
year = {2026},
volume = {64},
pages = {102646},
doi = {10.1016/j.tranon.2025.102646}
}
EUVIMED